Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform is a cutting-edge technology licensed from the Schepens Eye Research Institute of Massachusetts Eye and Ear (Harvard Medical School) and involves targeted delivery and expression of one or more nuclear hormone receptor genes in the disease tissues with the potential to treat multiple retinal diseases with one drug – “one to many.” OCU400 (AAV-NR2E3) is a novel gene therapy product candidate with the potential to be broadly effective in restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases. OCU410 (AAV-RORA) is a modifier gene therapy product candidate being developed for the treatment of dry age-related macular degeneration. OCU200 is a biologic product candidate in preclinical development for treating severely sight-threatening diseases like Diabetic Macular Edema, Diabetic Retinopathy, and Wet Age-Related Macular Degeneration.
Shankar Musunuri, PhD, MBA
Chairman of the Board, CEO and Co-Founder
Shankar Musunuri, PhD, MBA is Chairman of the Board, CEO and Co-Founder of Ocugen, Inc. Dr. Musunuri is a seasoned biotech veteran with more than 25 years of results-driven experience advancing and commercializing a diverse portfolio of products. Prior to co-founding Ocugen in 2013, Dr. Musunuri held leadership roles at numerous companies ranging from “Big Pharma” to novel start-up biotechs. Most recently, he founded Nuron Biotech, Inc., which he grew to a commercial company in less than three years, serving as President and CEO. Dr. Musunuri obtained his PhD in Pharmaceutical Sciences from the University of Connecticut and an MBA from Duke University’s Fuqua School of Business. Dr. Musunuri is a thought leader sharing his insights on gene therapy including the areas of strategic partnerships, regulatory review, and reimbursement strategy.